264 related articles for article (PubMed ID: 30267321)
21. An open-label study to evaluate the long-term safety and efficacy of lanadelumab for prevention of attacks in hereditary angioedema: design of the HELP study extension.
Riedl MA; Bernstein JA; Craig T; Banerji A; Magerl M; Cicardi M; Longhurst HJ; Shennak MM; Yang WH; Schranz J; Baptista J; Busse PJ
Clin Transl Allergy; 2017; 7():36. PubMed ID: 29043014
[TBL] [Abstract][Full Text] [Related]
22. A focus on the use of subcutaneous C1-inhibitor for treatment of hereditary angioedema.
Villavicencio MF; Craig T
Expert Rev Clin Immunol; 2020 May; 16(5):451-455. PubMed ID: 32237900
[TBL] [Abstract][Full Text] [Related]
23. [Experiencia inicial de Lanadelumab en una paciente mexicana con angioedema hereditario tipo I].
García-Rosas C; López-Tiro JJ; Contreras-Contreras A; Ruiz-Peñaloza M; Ortiz-Monteón ZE
Rev Alerg Mex; 2023 Sep; 70(4):194. PubMed ID: 37933935
[TBL] [Abstract][Full Text] [Related]
24. Healthcare utilization of patients with hereditary angioedema treated with lanadelumab and subcutaneous C1-inhibitor concentrate.
Riedl MA; Hinds DR; Prince PM; Alvord TM; Dosenovic S; Abdelhadi JF; Brownrigg JR; Camp CL; Machnig T; Banerji A
Allergy Asthma Proc; 2023 Jul; 44(4):275-282. PubMed ID: 37328263
[No Abstract] [Full Text] [Related]
25. Treatment of episodes of hereditary angioedema with C1 inhibitor: serial assessment of observed abnormalities of the plasma bradykinin-forming pathway and fibrinolysis.
Joseph K; Tholanikunnel TE; Kaplan AP
Ann Allergy Asthma Immunol; 2010 Jan; 104(1):50-4. PubMed ID: 20143645
[TBL] [Abstract][Full Text] [Related]
26. Long-term prevention of hereditary angioedema attacks with lanadelumab: The HELP OLE Study.
Banerji A; Bernstein JA; Johnston DT; Lumry WR; Magerl M; Maurer M; Martinez-Saguer I; Zanichelli A; Hao J; Inhaber N; Yu M; Riedl MA;
Allergy; 2022 Mar; 77(3):979-990. PubMed ID: 34287942
[TBL] [Abstract][Full Text] [Related]
27. Hereditary angioedema due to C1-inhibitor deficiency in Macedonia: clinical characteristics, novel SERPING1 mutations and genetic factors modifying the clinical phenotype.
Grivčeva-Panovska V; Košnik M; Korošec P; Andrejević S; Karadža-Lapić L; Rijavec M
Ann Med; 2018 May; 50(3):269-276. PubMed ID: 29513108
[TBL] [Abstract][Full Text] [Related]
28. [Hereditary angioedema due to C1-esterase inhibitor deficiency : novel approaches].
Stehlin F; Ribi C
Rev Med Suisse; 2020 Apr; 16(689):675-678. PubMed ID: 32270933
[TBL] [Abstract][Full Text] [Related]
29. Lanadelumab for the prevention of hereditary angioedema attacks: A real-world UK audit.
Dorr AD; Chopra C; Coulter TI; Dempster J; Dziadzio M; El-Shanawany T; Garcez T; Gompels M; Herriot R; Jain R; Levi M; Lorenzo L; Makki I; Mapazire E; Murng SHK; Noorani S; Savic S; Steele CL; Symons C; Tarzi M; Yong PFK; Kiani-Alikhan S
Allergy; 2023 May; 78(5):1369-1371. PubMed ID: 36510404
[No Abstract] [Full Text] [Related]
30. Investigational drugs in phase I and phase II clinical trials for hereditary angioedema.
Farkas H; Debreczeni ML; Kőhalmi KV
Expert Opin Investig Drugs; 2018 Jan; 27(1):87-103. PubMed ID: 29226721
[TBL] [Abstract][Full Text] [Related]
31. Deficiency of plasminogen activator inhibitor 2 in plasma of patients with hereditary angioedema with normal C1 inhibitor levels.
Joseph K; Tholanikunnel BG; Wolf B; Bork K; Kaplan AP
J Allergy Clin Immunol; 2016 Jun; 137(6):1822-1829.e1. PubMed ID: 26395818
[TBL] [Abstract][Full Text] [Related]
32. Recombinant human C1 esterase inhibitor for the treatment of hereditary angioedema due to C1 inhibitor deficiency (C1-INH-HAE).
Sabharwal G; Craig T
Expert Rev Clin Immunol; 2015 Mar; 11(3):319-27. PubMed ID: 25669442
[TBL] [Abstract][Full Text] [Related]
33. An evidence based therapeutic approach to hereditary and acquired angioedema.
Bork K
Curr Opin Allergy Clin Immunol; 2014 Aug; 14(4):354-62. PubMed ID: 24983294
[TBL] [Abstract][Full Text] [Related]
34. Effect of Lanadelumab Compared With Placebo on Prevention of Hereditary Angioedema Attacks: A Randomized Clinical Trial.
Banerji A; Riedl MA; Bernstein JA; Cicardi M; Longhurst HJ; Zuraw BL; Busse PJ; Anderson J; Magerl M; Martinez-Saguer I; Davis-Lorton M; Zanichelli A; Li HH; Craig T; Jacobs J; Johnston DT; Shapiro R; Yang WH; Lumry WR; Manning ME; Schwartz LB; Shennak M; Soteres D; Zaragoza-Urdaz RH; Gierer S; Smith AM; Tachdjian R; Wedner HJ; Hebert J; Rehman SM; Staubach P; Schranz J; Baptista J; Nothaft W; Maurer M;
JAMA; 2018 Nov; 320(20):2108-2121. PubMed ID: 30480729
[TBL] [Abstract][Full Text] [Related]
35. Efficacy of lanadelumab in angioedema due to acquired C1 inhibitor deficiency.
Suffritti C; Sartorio S; Berra S; Janu VP; Caccia S; Zanichelli A
J Allergy Clin Immunol Pract; 2023 Mar; 11(3):963-965.e1. PubMed ID: 36379410
[No Abstract] [Full Text] [Related]
36. Network meta-analysis for indirect comparison of lanadelumab and berotralstat for the treatment of hereditary angioedema.
Watt M; Malmenäs M; Romanus D; Haeussler K
J Comp Eff Res; 2023 Jun; 12(6):e220188. PubMed ID: 37218553
[No Abstract] [Full Text] [Related]
37. Hereditary and acquired angioedema.
Patel G; Pongracic JA
Allergy Asthma Proc; 2019 Nov; 40(6):441-445. PubMed ID: 31690390
[TBL] [Abstract][Full Text] [Related]
38. A Decade of Change: Recent Developments in Pharmacotherapy of Hereditary Angioedema (HAE).
Bork K
Clin Rev Allergy Immunol; 2016 Oct; 51(2):183-92. PubMed ID: 27207174
[TBL] [Abstract][Full Text] [Related]
39. Lanadelumab Efficacy, Safety, and Injection Interval Extension in HAE: A Real-Life Study.
Buttgereit T; Vera C; Weller K; Gutsche A; Grekowitz EM; Aykanat S; Wahn V; Krüger R; Maurer M; Magerl M
J Allergy Clin Immunol Pract; 2021 Oct; 9(10):3744-3751. PubMed ID: 34023564
[TBL] [Abstract][Full Text] [Related]
40. Genetics of Hereditary Angioedema Revisited.
Germenis AE; Speletas M
Clin Rev Allergy Immunol; 2016 Oct; 51(2):170-82. PubMed ID: 27116602
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
